about
Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questionsLimited importance of the dominant-negative effect of TP53 missense mutationsPIN3 duplication may be partially responsible for TP53 haploinsufficiencyDifferent mutational characteristics of TSG in cell lines and surgical specimensGlioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies.Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions.Prognostic role of tumour-infiltrating inflammatory cells in brain tumours: literature review.BRAF inhibitors in BRAF-V600 mutated primary neuroepithelial brain tumors.KINFix--A formalin-free non-commercial fixative optimized for histological, immunohistochemical and molecular analyses of neurosurgical tissue specimens.Urine F2-isoprostanes concentration as a poor prognostic factor after subarachnoid haemorrhage.The failure in the stabilization of glioblastoma-derived cell lines: spontaneous in vitro senescence as the main culprit.Detection of P53 mutations in different cancer types is improved by cDNA sequencing.Association of loss of heterozygosity with shorter survival in primary glioblastoma patients.Reduced expression of ELAVL4 in male meningioma patients.Bioimaging and surgery of brain tumors.Clinical neuropathology of brain tumors.Validation of nuclear STAT6 immunostaining as a diagnostic marker of meningeal solitary fibrous tumor (SFT)/hemangiopericytoma.Glioblastoma specimens with TP53 mutations do not show EGFRvIII amplification.Isoprostanes as potential cerebral vasospasm biomarkersMolecular diagnostic testing of diffuse gliomas in the real-life setting: A practical approachMAML2 rearrangement as a useful diagnostic marker discriminating between Warthin tumour and Warthin-like mucoepidermoid carcinomaRecurrent Pineocytomalike Papillary Tumor of The Pineal Region: A Case Report and Literature ReviewLiquid biopsy for minimally invasive heart transplant monitoring: a pilot studyPrimarily resectable pancreatic adenocarcinoma - to operate or to refer the patient to an oncologist?MiR-21, miR-34a, miR-125b, miR-181d and miR-648 levels inversely correlate with MGMT and TP53 expression in primary glioblastoma patients
P50
Q26795767-4C6474EA-63D6-4406-A402-5933B0C5019DQ33931015-69DB592C-40A9-4382-B486-289074B5B8E3Q34252210-B766389A-8280-4F8D-8D07-738209685D94Q34574381-101DDAFA-3039-4024-9C47-DAEB2E4EE95DQ34950060-56E2F12F-81B5-4B84-97EE-DB8C5FFF25CAQ38411964-0CB2FBAA-06A5-426C-96FB-10B7C5C64BC9Q38592194-77BB7B28-17DA-4898-A65D-9BDFA8941922Q38625131-92E4DA27-C1A9-4DA0-86EA-11CCDDFDE0B1Q38625594-517EB578-7792-4E32-A2DC-15C8B11830E2Q38637454-D2E4ABAF-471D-48DC-8D9F-1EB3BBFD5137Q39027058-07E642E2-05E2-463A-979F-C16DC0990D4DQ42323670-A16B7CDF-ABF9-4C7A-8B8F-4E4D16B9BA77Q45162831-A815DA82-ECAF-4778-A859-4138ADD8D4F6Q45399334-586055E8-14F6-44C9-8894-EFD9BAF81510Q47846223-E92A31E3-B7BF-4CF8-8DBD-ED2CE1C76A9FQ48029486-CBF85EBA-9E5E-4BC8-804F-4FDBC5E00F6DQ51166029-B888706B-C78E-4011-B2D0-7F86D46987B6Q54582810-83A48A33-5EA2-4A61-B098-CB26427F73B6Q57483908-1C10DD34-E812-48DB-A6BC-7AF8BF80EB47Q89163281-C06E537B-32D9-40A8-940D-566A69E0136DQ90722929-58D47A4F-09FF-4685-96B1-50177F540234Q91232882-DA9ED3B1-26CA-4484-AF32-DBB15DBF2396Q91735059-F72545C9-35F0-4A95-9AB4-E7CA20A513B8Q92019362-0E4F195B-5B60-40DE-B849-03C1D64762E7Q92540204-33777888-C3B0-4DA7-A438-A47E987F6B59
P50
description
Pools onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michał Bieńkowski
@ast
Michał Bieńkowski
@ca
Michał Bieńkowski
@cs
Michał Bieńkowski
@en
Michał Bieńkowski
@es
Michał Bieńkowski
@gl
Michał Bieńkowski
@hr
Michał Bieńkowski
@hsb
Michał Bieńkowski
@it
Michał Bieńkowski
@nl
type
label
Michał Bieńkowski
@ast
Michał Bieńkowski
@ca
Michał Bieńkowski
@cs
Michał Bieńkowski
@en
Michał Bieńkowski
@es
Michał Bieńkowski
@gl
Michał Bieńkowski
@hr
Michał Bieńkowski
@hsb
Michał Bieńkowski
@it
Michał Bieńkowski
@nl
prefLabel
Michał Bieńkowski
@ast
Michał Bieńkowski
@ca
Michał Bieńkowski
@cs
Michał Bieńkowski
@en
Michał Bieńkowski
@es
Michał Bieńkowski
@gl
Michał Bieńkowski
@hr
Michał Bieńkowski
@hsb
Michał Bieńkowski
@it
Michał Bieńkowski
@nl
P214
P106
P1153
56900931600
P1412
P1559
Michał Bieńkowski
@pl
P21
P214
P27
P31
P3124
P496
0000-0002-9291-3928
P734
P735
P7859
viaf-317138014